Francis Szoka, PhD

Phone: +1 415 476-3895
Fax: +1 415 476-2744

513 Parnassus Ave, Rm 1145B
UCSF Box 0912
San Francisco, CA 94143
United States

What I do

I apply biophysics, chemistry, and immunology to understand and devise better ways to deliver drugs, proteins, and nucleic acids to treat cancer and infectious diseases.

My research expertise

Physico-chemical properties of phospholipid bilayers, Biomembrane fusion, Phospholipid bilayer vesicles (liposomes) for pharmaceutical applications, Macromolecule delivery across membrane, Genetic disease, Cancer, HIV Vaccine, Cell-based therapies

Degrees

PhD, Biochemistry, University at Buffalo (The State University of New York), 1976
MS, Microbiology, University of Maryland, 1971
BA, Liberal Arts, Johns Hopkins University, 1965

Biography

The Szoka group applies chemical, biophysical and molecular biology approaches to devise vaccine, drug and nucleic acid delivery systems to treat cancer or infectious diseases. These systems can incorporate lipids, peptides, polymers and proteins. These drug carriers are composed of lipids, polymers, peptides or proteins. His group has extensively investigated the role of lipids in membrane fusion and his designed, synthesized and studied the mechanism of fusogenic peptides. With group members, he has published over 195 manuscripts and has received 26 U.S. patents. One FDA approved drug product Amphotec™ and one biotechnology product Superfect™ have been commercialized from the patents. In addition to his University commitments, Dr. Szoka is a founder of Sequus Pharmaceuticals, Inc. owned by Johnson & Johnson and GeneMedicine, inc. now known as Valentis, Inc. Sequus introduced sterically stabilized liposomes for anti-cancer drug delivery (Doxil™).